The strategy to use adenoviral-mediated CD40L gene therapy to induce anti-tumor immunity has been employed in several cancer models [36] and it has recently been evaluated in a phase I/IIa clinical trial for bladder carcinoma [37]. Here, CD40LG is linked to urinary bladder carcinoma.